Clinical Trial Update: Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab plus cetuximab and irinotecan versus third-line standard-of-care in refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms Malignant

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Colorectal Neoplasms Malignant | Phase 2 | Status: UNKNOWN